EUCTR2010-022971-79-CZ进行中（未招募）不适用
A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent to be signed by parent(s) of the pediatric patient in compliance with the local law regulations. In addition signed children’s assent form according to local requirements.
- •2.Male or female patient aged from 1 month to less than 17 years.
- •3.In-patient or out-patient scheduled to undergo one of the following procedures:
- •ear, nose and throat surgery (e.g., tonsillectomy, adenoidectomy, myringotomy),
- •eye surgery (e.g. strabismus, vitreoretinal, cataract surgery),
- •urological surgery (e.g. orchidopexy, varicocoele)
- •plastic reconstructive surgery (e.g. cleft lip/cleft palate, burn procedures involving the scalp),
- •hernia repair,
- •orthopedic surgery (e.g. foot and ankle deformities, arthroscopic surgeries, ACL surgery)
- •cardiac surgery,
- •neurosurgery.
- •4.Patient is scheduled to undergo surgery requiring general intravenous anesthesia.
- •5.Patient scheduled to receive nitrous oxide during the maintenance phase of anesthesia.
- •6.Patient weight at least 3.2 kg.
- •7.ASA physical status I, II or III.
- •8.Sexually active patients (male or female) must use double-barrier contraception method for patients and sexual partners.
- •9.Female patients who have attained menarche must have a negative pregnancy test at the screening visit (Visit 1) and at study treatment visit (Visit 2). The patient and her parent(s) must be counseled on the importance of not becoming pregnant before or during the study.
- •10.For patients with known hepatic impairment: in the investigator’s opinion the impairment does not jeopardize patient’s safety during the study.
- •11.For patients with known renal impairment: in the investigator’s opinion the impairment does not jeopardize patient’s safety during the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 660
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The patient and/or parents/caregivers are expected by the Investigator to be non-compliant with the study procedures.
- •2. Lactating females.
- •3. Patient aged =6 years who received any investigational drug within 90 days prior to Day 1, or patient aged >6 who received any investigational drug within 30 days prior to Day 1 or is expected to receive investigational drugs prior to study completion.
- •4. Patient having participated in any previous trial with palonosetron.
- •5. History of allergy to any components or any other contraindications to the use of any 5-HT3 receptor antagonists.
- •6. Patient to undergo emergency surgery.
- •7. Patient scheduled to receive regional anesthesia (lumbar, epidural, spinal) alone or in conjunction with general intravenous anesthesia.
- •8. Patient scheduled to receive laryngeal mask anesthesia.
- •9. Patient scheduled to receive propofol during the maintenance phase of anesthesia.
- •10. Patient scheduled to receive intragastric tube in situ postoperatively.
- •11. Patient suffering from any concomitant disease uncontrolled by therapy, which, at the judgment of the Investigator, could compromise the outcome of surgery.
- •12. Patient with history of gastro-esophageal reflux (except for patients up to 12 months).
- •13. Patient with ongoing vomiting from any organic cause.
- •14. Patient having experienced any vomiting, retching, or nausea within 24 hours prior to the administration of the study drug.
- •15. Use of any of the following drug with potential anti-emetic effect within 48h prior to surgery (Appendix D):
- •5-HT3 antagonists (e.g., ondansetron, granisetron, dolasetron);
- •Phenothiazines (e.g., perphenazine, prochlorperazine, promethazine, fluphenazine, chlorpromazine, thiethylperazine);
- •Butyrophenones (e.g., droperidol, haloperidol);
- •Benzamides (e.g., metoclopramide, alizapride);
- •Systemic corticosteroids (e.g., dexamethasone, prednisone, methylprednisolone; except inhaled steroids for respiratory disorders and topical steroids for skin disease);
- •Dimenhydrinate; hydroxyzine; domperidone; lorazepam; cyclizine; cannabinoids; scopolamine; trimetobenzamide HCl; meclizine hydrochloride; pseudoephedrine HCl;
- •Over the Counter (OTC) antiemetics, OTC cold or OTC allergy medications;
- •Herbal preparations containing ephedra or ginger.
研究者
相似试验
进行中（未招募）
不适用
ot applicableEUCTR2010-022971-79-PLHelsinn Healthcare SA660
进行中（未招募）
不适用
A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsEvaluate the efficacy of a single palonosetron IV dose to prevent postoperative nausea and vomiting through 24 hours.Evaluate the safety and tolerability of IV palonosetron in pediatric patients.MedDRA version: 13.1Level: LLTClassification code 10036238Term: Postoperative vomitingSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 13.1Level: LLTClassification code 10036285Term: Postoperative nauseaSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2010-022971-79-HUHelsinn Healthcare SA660
已完成
3 期
A clinical study to assess the efficacy and safety of combination of Dapagliflozin and Sitagliptin phosphate tablets in comparison to Sitagliptin phosphate tablets as an additional treatment to Metformin tablets in patients with type 2 diabetesCTRI/2021/06/033962Sun Pharma Laboratories Limited389
招募中
不适用
A multicenter, double-blind, double-dummy, randomized controlled trial of the Chinese herbal medicine Linggui granule for patients with asthenospermiaasthenospermiaITMCTR2200005858Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
进行中（未招募）
不适用
A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea - NDThe primary objective of this study is to show superiority of SH T00658ID over SH D593B with respect to the number of days with dysmenorrheic pain in a defined period, i.e. comparison between two baseline cycles and two treatment cycles.MedDRA version: 9.1Level: LLTClassification code 10030970Term: Oral contraceptionEUCTR2008-005625-11-ITBayer Healthcare AG580